January 10, 2022, Toronto, CANADA — BenchSci, a Toronto-based hypergrowth company developing the world’s most advanced biomedical AI to exponentially increase the speed and quality of life-saving research, announced today it has signed an agreement with Oxford University Press (OUP).
This important agreement gives BenchSci’s proprietary machine learning technology access to over 120 bioscience journals (including closed- and open-access, and hybrid journals) such as European Heart Journal, Nucleic Acids Research, Neuro-Oncology, and Clinical Infectious Diseases. BenchSci's proprietary AI-powered technology will decode the scientific insights from the data contained in these closed-access journals, providing scientists with valuable insights to plan, procure for, and execute experiments more effectively.
“We’re proud to partner with such an eminent publisher of scientific journals. Combined with our technology, the biological data from the Oxford University Press publications will further enable scientists to analyze and extract critical experimental insights to accelerate their research programs,” says Liran Belenzon, CEO, BenchSci. “The addition of these journals greatly expands scientists’ access to more quality data, resulting in more informed decisions on experimental design and more successful experiments, bringing medicine to patients faster.”
BenchSci’s machine learning technology decodes the world’s most comprehensive biomedical dataset like a Ph.D. scientist to inform the next big discoveries and breakthroughs. Scientists use BenchSci to glean critical experimental insights from high-impact sources specific to their target of interest and experimental context. This improves the speed and success of their experiments.
“We are pleased to be able to provide content from our journals and society partners to the BenchSci platform, and look forward to seeing the interest from scientists,” said Alison Denby, VP Journals, OUP. “We believe that this relationship is a big step in leveraging modern AI techniques in a way that will directly improve the impact of the research we publish, and channel it more rapidly and effectively into the hands of researchers that need it."
Data from OUP will be rolling out to BenchSci customers in upcoming product releases.
For more BenchSci updates, visit our news page.
BenchSci’s vision is to bring novel medicine to patients 50% faster by 2025. We’re achieving it by empowering scientists with the world’s most advanced biomedical artificial intelligence to run more successful experiments. Backed by F-Prime, Gradient Ventures (Google’s AI fund), and Inovia Capital, our platform accelerates science at 15 top-20 pharmaceutical companies and over 4,300 leading research centers worldwide. We’re a Deloitte Tech Fast 50 and CIX Top 10 Growth company, certified Great Place to Work®, and top-ranked company on Glassdoor. Learn more at www.benchsci.com.
For more information, please contact Marie Cook at email@example.com.